In 2026, the Non-alcoholic Steatohepatitis (NASH) market—now increasingly referred to by the updated scientific nomenclature MASH (Metabolic Dysfunction-Associated Steatohepatitis)—is at a historic tipping point. Following the first landmark FDA approvals in 2024, the market has transitioned from a "graveyard of clinical trials" to one of the most lucrative frontiers in cardiometabolic medicine.
Global NASH/MASH Market Overview
The global NASH market was valued at USD 9.21 billion in 2025 and is projected to reach USD 98.42 billion by 2036, growing at a staggering CAGR of 23.8%.
The surge is primarily driven by the "triple threat" of rising obesity, Type 2 diabetes, and sedentary lifestyles globally. In 2026, the market is no longer just about liver health; it is being integrated into the broader GLP-1/Obesity ecosystem, with pharmaceutical leaders positioning NASH treatments as essential for long-term metabolic management.
Key Players Covered
The 2026 landscape is divided between early movers with approved therapies and biopharma giants with high-potential pipelines.
| Market Leaders (Approved) | Pipeline Innovators (Phase II/III) | Diagnostic & AI Partners |
| Madrigal Pharmaceuticals (Rezdiffra) | 89bio (Pegozafermin) | Echosens (FibroScan) |
| Novo Nordisk (Semaglutide/Wegovy) | Akero Therapeutics (Efruxifermin) | Labcorp/Quest Diagnostics |
| Zydus Lifesciences (Saroglitazar) | Viking Therapeutics (VK2809) | Perspectum (LiverMultiScan) |
| Gilead Sciences | Boehringer Ingelheim (Survodutide) | HistoIndex (AI Pathology) |
| Intercept Pharmaceuticals | Inventiva Pharma (Lanifibranor) | PathAI |
Market Segmentation
By Drug Class
-
Thyroid Hormone Receptor (THR)-β Agonists: Currently leading due to first-mover advantage (e.g., Resmetirom).
-
GLP-1 and Dual/Triple Agonists: The fastest-growing segment, leveraging the massive infrastructure of anti-obesity medications.
-
FGF21 Analogs: Targeted for patients with advanced fibrosis.
-
PPAR Agonists: Addressing insulin sensitivity and inflammation.
By Disease Stage
-
Fibrotic NASH (F2–F3): The primary target for current pharmacotherapy.
-
Cirrhotic NASH (F4): A high-unmet-need segment with fewer treatment options but high potential for orphan drug status.
Strategic Market Frameworks
Porter’s Five Forces
-
Bargaining Power of Buyers (Moderate): Increasing as payers demand "outcome-based" pricing and non-invasive proof of improvement.
-
Threat of New Entrants (High): Dozens of biotech firms are entering the space with novel mechanisms of action (MoA).
-
Competitive Rivalry (Extreme): A race to dominate the primary care market, with companies competing on dosing (oral vs. injectable).
SWOT Analysis
-
Strengths: Massive patient pool (>115M globally); high clinical unmet need.
-
Weaknesses: Historical high failure rate in clinical trials; high cost of novel therapies.
-
Opportunities: Transitioning from liver biopsy to Non-Invasive Tests (NITs) for diagnosis.
-
Threats: Strict regulatory hurdles for histological endpoints.
Trend Analysis: Drivers & Challenges
-
The Rebranding Effect: The shift to MASH highlights the metabolic origin of the disease, making it easier for primary care physicians to identify and treat patients.
-
Non-Invasive Diagnosis: The "death of the biopsy" is near; 2026 sees the widespread adoption of blood-based biomarkers and elastography.
-
Challenge: Patient Compliance. Long-term treatment is required to reverse fibrosis, making "silent disease" adherence difficult.
Value Chain Analysis
-
Biomarker Discovery: Identifying high-risk patients via serum panels.
-
Drug Development: Focus on multi-target therapies (liver + heart + metabolism).
-
Specialized Distribution: Growth of Specialty Pharmacies to manage high-cost biologics.
-
Integrated Care: Clinics offering nutrition, endocrinology, and hepatology in one "metabolic hub."
Quick Recommendations for Stakeholders
-
For Pharma: Focus on Combination Therapies. NASH is a multi-pathway disease; single-target drugs may not suffice for all patients.
-
For Diagnostic Labs: Scale Blood-Based Panels. Scalable, cheap alternatives to imaging are the key to unlocking the mass-market diagnostic potential.
-
For Investors: Look for companies with strong Phase 2b data in Fibrosis (F3), as this remains the most critical "approvable" endpoint.
1. Market Overview of Non-alcoholic Steatohepatitis
1.1 Non-alcoholic Steatohepatitis Market Overview
1.1.1 Non-alcoholic Steatohepatitis Product Scope
1.1.2 Market Status and Outlook
1.2 Non-alcoholic Steatohepatitis Market Size by Regions:
1.3 Non-alcoholic Steatohepatitis Historic Market Size by Regions
1.4 Non-alcoholic Steatohepatitis Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Non-alcoholic Steatohepatitis Sales Market by Type
2.1 Global Non-alcoholic Steatohepatitis Historic Market Size by Type
2.2 Global Non-alcoholic Steatohepatitis Forecasted Market Size by Type
2.3 Solid
2.4 Liquid
3. Covid-19 Impact Non-alcoholic Steatohepatitis Sales Market by Application
3.1 Global Non-alcoholic Steatohepatitis Historic Market Size by Application
3.2 Global Non-alcoholic Steatohepatitis Forecasted Market Size by Application
3.3 Oral
3.4 Parenteral
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Non-alcoholic Steatohepatitis Production Capacity Market Share by Manufacturers
4.2 Global Non-alcoholic Steatohepatitis Revenue Market Share by Manufacturers
4.3 Global Non-alcoholic Steatohepatitis Average Price by Manufacturers
5. Company Profiles and Key Figures in Non-alcoholic Steatohepatitis Business
5.1 AstraZeneca
5.1.1 AstraZeneca Company Profile
5.1.2 AstraZeneca Non-alcoholic Steatohepatitis Product Specification
5.1.3 AstraZeneca Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.2 Arena Pharmaceuticals
5.2.1 Arena Pharmaceuticals Company Profile
5.2.2 Arena Pharmaceuticals Non-alcoholic Steatohepatitis Product Specification
5.2.3 Arena Pharmaceuticals Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.3 GSK
5.3.1 GSK Company Profile
5.3.2 GSK Non-alcoholic Steatohepatitis Product Specification
5.3.3 GSK Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.4 Novo Nordisk
5.4.1 Novo Nordisk Company Profile
5.4.2 Novo Nordisk Non-alcoholic Steatohepatitis Product Specification
5.4.3 Novo Nordisk Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.5 Roche
5.5.1 Roche Company Profile
5.5.2 Roche Non-alcoholic Steatohepatitis Product Specification
5.5.3 Roche Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.6 Vivus
5.6.1 Vivus Company Profile
5.6.2 Vivus Non-alcoholic Steatohepatitis Product Specification
5.6.3 Vivus Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.7 Arisaph Pharmaceuticals
5.7.1 Arisaph Pharmaceuticals Company Profile
5.7.2 Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Product Specification
5.7.3 Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.8 Cempra Pharmaceuticals
5.8.1 Cempra Pharmaceuticals Company Profile
5.8.2 Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Product Specification
5.8.3 Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.9 Galectin Therapeutics
5.9.1 Galectin Therapeutics Company Profile
5.9.2 Galectin Therapeutics Non-alcoholic Steatohepatitis Product Specification
5.9.3 Galectin Therapeutics Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.10 Galmed Pharmaceuticals
5.10.1 Galmed Pharmaceuticals Company Profile
5.10.2 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Product Specification
5.10.3 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.11 Genfit
5.11.1 Genfit Company Profile
5.11.2 Genfit Non-alcoholic Steatohepatitis Product Specification
5.11.3 Genfit Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.12 Gilead
5.12.1 Gilead Company Profile
5.12.2 Gilead Non-alcoholic Steatohepatitis Product Specification
5.12.3 Gilead Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.13 Immuron
5.13.1 Immuron Company Profile
5.13.2 Immuron Non-alcoholic Steatohepatitis Product Specification
5.13.3 Immuron Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.14 Interceptpharma
5.14.1 Interceptpharma Company Profile
5.14.2 Interceptpharma Non-alcoholic Steatohepatitis Product Specification
5.14.3 Interceptpharma Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.15 Raptor Pharmaceutical
5.15.1 Raptor Pharmaceutical Company Profile
5.15.2 Raptor Pharmaceutical Non-alcoholic Steatohepatitis Product Specification
5.15.3 Raptor Pharmaceutical Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.16 Shire
5.16.1 Shire Company Profile
5.16.2 Shire Non-alcoholic Steatohepatitis Product Specification
5.16.3 Shire Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.17 Tobira Therapeutics
5.17.1 Tobira Therapeutics Company Profile
5.17.2 Tobira Therapeutics Non-alcoholic Steatohepatitis Product Specification
5.17.3 Tobira Therapeutics Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.18 Verva
5.18.1 Verva Company Profile
5.18.2 Verva Non-alcoholic Steatohepatitis Product Specification
5.18.3 Verva Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
5.19 Viking Therapeutics
5.19.1 Viking Therapeutics Company Profile
5.19.2 Viking Therapeutics Non-alcoholic Steatohepatitis Product Specification
5.19.3 Viking Therapeutics Non-alcoholic Steatohepatitis Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Non-alcoholic Steatohepatitis Market Size
6.2 North America Non-alcoholic Steatohepatitis Key Players in North America
6.3 North America Non-alcoholic Steatohepatitis Market Size by Type
6.4 North America Non-alcoholic Steatohepatitis Market Size by Application
7. East Asia
7.1 East Asia Non-alcoholic Steatohepatitis Market Size
7.2 East Asia Non-alcoholic Steatohepatitis Key Players in North America
7.3 East Asia Non-alcoholic Steatohepatitis Market Size by Type
7.4 East Asia Non-alcoholic Steatohepatitis Market Size by Application
8. Europe
8.1 Europe Non-alcoholic Steatohepatitis Market Size
8.2 Europe Non-alcoholic Steatohepatitis Key Players in North America
8.3 Europe Non-alcoholic Steatohepatitis Market Size by Type
8.4 Europe Non-alcoholic Steatohepatitis Market Size by Application
9. South Asia
9.1 South Asia Non-alcoholic Steatohepatitis Market Size
9.2 South Asia Non-alcoholic Steatohepatitis Key Players in North America
9.3 South Asia Non-alcoholic Steatohepatitis Market Size by Type
9.4 South Asia Non-alcoholic Steatohepatitis Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Non-alcoholic Steatohepatitis Market Size
10.2 Southeast Asia Non-alcoholic Steatohepatitis Key Players in North America
10.3 Southeast Asia Non-alcoholic Steatohepatitis Market Size by Type
10.4 Southeast Asia Non-alcoholic Steatohepatitis Market Size by Application
11. Middle East
11.1 Middle East Non-alcoholic Steatohepatitis Market Size
11.2 Middle East Non-alcoholic Steatohepatitis Key Players in North America
11.3 Middle East Non-alcoholic Steatohepatitis Market Size by Type
11.4 Middle East Non-alcoholic Steatohepatitis Market Size by Application
12. Africa
12.1 Africa Non-alcoholic Steatohepatitis Market Size
12.2 Africa Non-alcoholic Steatohepatitis Key Players in North America
12.3 Africa Non-alcoholic Steatohepatitis Market Size by Type
12.4 Africa Non-alcoholic Steatohepatitis Market Size by Application
13. Oceania
13.1 Oceania Non-alcoholic Steatohepatitis Market Size
13.2 Oceania Non-alcoholic Steatohepatitis Key Players in North America
13.3 Oceania Non-alcoholic Steatohepatitis Market Size by Type
13.4 Oceania Non-alcoholic Steatohepatitis Market Size by Application
14. South America
14.1 South America Non-alcoholic Steatohepatitis Market Size
14.2 South America Non-alcoholic Steatohepatitis Key Players in North America
14.3 South America Non-alcoholic Steatohepatitis Market Size by Type
14.4 South America Non-alcoholic Steatohepatitis Market Size by Application
15. Rest of the World
15.1 Rest of the World Non-alcoholic Steatohepatitis Market Size
15.2 Rest of the World Non-alcoholic Steatohepatitis Key Players in North America
15.3 Rest of the World Non-alcoholic Steatohepatitis Market Size by Type
15.4 Rest of the World Non-alcoholic Steatohepatitis Market Size by Application
16 Non-alcoholic Steatohepatitis Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter’s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Key Players Covered
The 2026 landscape is divided between early movers with approved therapies and biopharma giants with high-potential pipelines.
| Market Leaders (Approved) | Pipeline Innovators (Phase II/III) | Diagnostic & AI Partners |
| Madrigal Pharmaceuticals (Rezdiffra) | 89bio (Pegozafermin) | Echosens (FibroScan) |
| Novo Nordisk (Semaglutide/Wegovy) | Akero Therapeutics (Efruxifermin) | Labcorp/Quest Diagnostics |
| Zydus Lifesciences (Saroglitazar) | Viking Therapeutics (VK2809) | Perspectum (LiverMultiScan) |
| Gilead Sciences | Boehringer Ingelheim (Survodutide) | HistoIndex (AI Pathology) |
| Intercept Pharmaceuticals | Inventiva Pharma (Lanifibranor) | PathAI |
Market Segmentation
By Drug Class
-
Thyroid Hormone Receptor (THR)-β Agonists: Currently leading due to first-mover advantage (e.g., Resmetirom).
-
GLP-1 and Dual/Triple Agonists: The fastest-growing segment, leveraging the massive infrastructure of anti-obesity medications.
-
FGF21 Analogs: Targeted for patients with advanced fibrosis.
-
PPAR Agonists: Addressing insulin sensitivity and inflammation.
By Disease Stage
-
Fibrotic NASH (F2–F3): The primary target for current pharmacotherapy.
-
Cirrhotic NASH (F4): A high-unmet-need segment with fewer treatment options but high potential for orphan drug status.
